Drug Trial Radar · NCT03567824
MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Pharmalyte Solutions LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10 mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.
Conditions
- Hypomagnesemia in Type 2 Diabetic Patients
Interventions
Magnesium L-lactate dihydrateDrug
Magnesium L-lactate dihydrate 10 mEq extended release caplets
Placebo Oral TabletDrug
Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Serum Magnesium ConcentrationTime frame: Three months after the initiation of treatment and then at 3 months after the start of the random off phase.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.